Corporate Responsibility Report

Overview

The report describes Cytokinetics' 2024 momentum as it prepared for the potential approval and launch of aficamten while advancing its cardiovascular and neuromuscular pipeline. It highlights patient engagement, company-wide inclusion training, and the launch of a Corporate Giving Program supporting 26 organizations. The report also describes Sustainability Committee initiatives on energy reduction, waste minimization and laboratory-plastics recycling, alongside disclosed Scope 1 and Scope 2 emissions data.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services